These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 37953496)
1. Acquired and intrinsic resistance to vemurafenib in BRAF Zhang P; Kuil LE; Buil LCM; Freriks S; Beijnen JH; van Tellingen O; de Gooijer MC FEBS Open Bio; 2024 Jan; 14(1):96-111. PubMed ID: 37953496 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455 [TBL] [Abstract][Full Text] [Related]
3. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535 [TBL] [Abstract][Full Text] [Related]
4. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. Mittapalli RK; Vaidhyanathan S; Dudek AZ; Elmquist WF J Pharmacol Exp Ther; 2013 Mar; 344(3):655-64. PubMed ID: 23249624 [TBL] [Abstract][Full Text] [Related]
6. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. Michaelis M; Rothweiler F; Nerreter T; van Rikxoort M; Zehner R; Dirks WG; Wiese M; Cinatl J BMC Res Notes; 2014 Oct; 7():710. PubMed ID: 25300205 [TBL] [Abstract][Full Text] [Related]
7. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583 [TBL] [Abstract][Full Text] [Related]
9. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
11. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy. Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666 [TBL] [Abstract][Full Text] [Related]
12. BRAF Inhibitors in Melanoma Management: When Friends Become Foes. Chhabra G; Ahmad N J Invest Dermatol; 2022 May; 142(5):1256-1259. PubMed ID: 34872726 [TBL] [Abstract][Full Text] [Related]
13. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143 [TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Wang J; Gan C; Sparidans RW; Wagenaar E; van Hoppe S; Beijnen JH; Schinkel AH Pharmacol Res; 2018 Mar; 129():414-423. PubMed ID: 29155017 [TBL] [Abstract][Full Text] [Related]
15. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630 [TBL] [Abstract][Full Text] [Related]
16. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier. Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927 [TBL] [Abstract][Full Text] [Related]
17. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512 [TBL] [Abstract][Full Text] [Related]
18. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice. Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951 [TBL] [Abstract][Full Text] [Related]
19. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Hu W; Jin L; Jiang CC; Long GV; Scolyer RA; Wu Q; Zhang XD; Mei Y; Wu M Cell Death Dis; 2013 Nov; 4(11):e914. PubMed ID: 24201813 [TBL] [Abstract][Full Text] [Related]
20. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]